A promising on-demand treatment option for bleeding events in haemophilia patients with inhibitors.

about

A promising on-demand treatment option for bleeding events in haemophilia patients with inhibitors.

Item

http://www.wikidata.org/entity/Q45874627

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

A promising on-demand treatmen ...... ilia patients with inhibitors.

@en

A promising on-demand treatmen ...... ilia patients with inhibitors.

@nl

type

Item

label

A promising on-demand treatmen ...... ilia patients with inhibitors.

@en

A promising on-demand treatmen ...... ilia patients with inhibitors.

@nl

prefLabel

A promising on-demand treatmen ...... ilia patients with inhibitors.

@en

A promising on-demand treatmen ...... ilia patients with inhibitors.

@nl

P1476

A promising on-demand treatmen ...... ilia patients with inhibitors.

@en

P2093

Amy D Shapiro

http://www.w3.org/2001/XMLSchema#string

P2860

Toward optimal therapy for inhibitors in hemophilia

Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX

Therapeutic choices for patients with hemophilia and high-titer inhibitors.

Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa.

First 20 years with recombinant FVIIa (NovoSeven).

The effects of joint disease, inhibitors and other complications on health-related quality of life among males with severe haemophilia A in the United States.

Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.

Kinetic analysis and binding studies of a new recombinant human factor VIIa for treatment of haemophilia.

Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008).

Emicizumab Prophylaxis in Hemophilia A with Inhibitors.

P304

810-811

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/HAE.13345

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29149550

http://www.w3.org/2001/XMLSchema#string